Triscend ii six-month data for first 150 patients successfully demonstrate safety and efficacy of edwards evoque system for severe tricuspid regurgitation

San francisco , oct. 26, 2023 /prnewswire/ -- edwards lifesciences corporation (nyse: ew) today announced successful results from triscend ii, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking evoque tricuspid valve replacement system with optimal medical therapy (omt) compared to omt alone with 2:1 randomization. the outcomes for the first 150 patients of the triscend ii trial achieved the primary safety endpoint at 30 days and both co-primary effectiveness endpoints at six months, demonstrating superiority to omt alone.
EW Ratings Summary
EW Quant Ranking